Nuveen’s Biogen BIIB Stock Holding History

Nuveen’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,200	Closed	-$4K	–	3189
2022 Q3	$4K	Buy	+13,200	New	+$2.8M	﹤0.01%	3212

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen's BIIB Position: Q1 2026 in Review

Nuveen reduced its Biogen (BIIB) stake by 4.5% in Q1 2026, selling an estimated $3.08M and leaving 358,838 shares worth $65.8M. The position accounts for 0.02% of the portfolio, ranked #532.

Nuveen first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $371M in Q4 2019. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Nuveen held 358,838 shares of Biogen worth $65.8M as of Q1 2026.
Nuveen sold 16,719 Biogen shares in Q1 2026, an estimated $3.08M.
Biogen made up 0.02% of Nuveen's portfolio in Q1 2026, its #532 holding.
Nuveen first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
Nuveen's Biogen position peaked at $371M in Q4 2019.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.